11:33 AM EST - VBI Vaccines Inc. : Reported interim results from an ongoing Phase IV postmarketing study to evaluate Sci-B-Vac™, VBI's licensed third-generation hepatitis B vaccine, in healthy adults. In its interim analysis, Sci-B-Vac™ was found to be well-tolerated and demonstrated rapid onset of protection against the hepatitis B virus. VBI Vaccines Inc.
shares T.VBV are trading up $0.10 at $4.35.
